Getting Competition Down to a Science: The Effects of Technological Competition on Firms' Scientific Publications

References

• Afuah A. (2002) Mapping technological capabilities into product markets and competitive advantage: The case of cholesterol drugs. Strategic Management J. 23(2) 171–179.Crossref, Google Scholar
• Akerlof G. A. (1970) The market for “lemons”: Quality uncertainty and the market mechanism. Quart. J. Econom. 84(3) 488–500.Crossref, Google Scholar
• Anderson P., Tushman M. L. (1990) Technological discontinuities and dominant designs: A cyclical model of technological change. Admin. Sci. Quart. 35(4) 604–633.Crossref, Google Scholar
• Angell M. (2008) Industry-sponsored clinical research. J. Amer. Medical Assoc. 300(9) 1069–1071.Crossref, Google Scholar
• Appel L. J. (2002) The verdict from ALLHAT—Thiazide diuretics are the preferred initial therapy for hypertension. J. Amer. Medical Assoc. 288(23) 3039–3042.Crossref, Google Scholar
• Arrow K. J. (1962) Economic welfare and the allocation of resources for invention. The Rate and Direction of Inventive Activity: Economic and Social Factors—National Bureau of Economic Research. (Princeton University Press, Princeton, NJ) , 602–626.Crossref, Google Scholar
• Avorn J., Chen M., Hartley R. (1982) Scientific versus commercial sources of influence on the prescribing behavior of physicians. Amer. J. Medicine 73(1) 4–8.Crossref, Google Scholar
• Azoulay P. (2002) Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4) 551–594.Crossref, Google Scholar
• Balter W., Skelton M., Safir P. O. (2003) The p's and q's of publication planning. Pharmaceutical Executive 23(5) 130–136.Google Scholar
• Barney J. (1991) Firm resources and sustained competitive advantage. J. Management 17(1) 99–120.Crossref, Google Scholar
• Bijker W. E. (1987) The social construction of Bakelite: Toward a theory of invention. , Bijker W. E., Hughes T. P., Pinch T. J., eds. The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology. (MIT Press, Cambridge, MA) , 159–190.Google Scholar
• Blumenthal D., Causino N., Campbell E., Louis K. S. (1996) Relationships between academic institutions and industry in the life sciences—An industry survey. New Engl. J. Medicine 334(6) 368–373.Crossref, Google Scholar
• Bodewitz H. J. H. W., Buurma H., de Vries G. H. (1987) Regulatory science and the social management of trust in medicine. , Bijker W. E., Hughes T. P., Pinch T. J., eds. The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology. (MIT Press, Cambridge, MA) , 243–260.Google Scholar
• Bosch J.-C., Lee I. (1994) Wealth effects of Food and Drug Administration (FDA) decisions. Managerial Decision Econom. 15(6) 589–599.Crossref, Google Scholar
• Carpenter D. P. (2004) The political economy of FDA drug review: Processing, politics, and lessons for policy. Health Affairs 23(1) 52–63.Crossref, Google Scholar
• Center for Drug Evaluation and Research (2005) Report to the nation: Improving public health through human drugs. . Report, U.S. Department of Health and Human Services, Washington, DC. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078935.pdf.Google Scholar
• Christensen C. M. (1997) The Innovator's Dilemma: The Revolutionary Book that Will Change the Way You Do Business. (Harvard Business School Press, Boston) .Google Scholar
• Cockburn I. M., Henderson R. M. (1998) Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. J. Indust. Econom. 46(2) 157–182.Crossref, Google Scholar
• Cohen M. D., Bacdayan P. (1994) Organizational routines are stored as procedural memory: Evidence from a laboratory study. Organ. Sci. 5(4) 554–568.Link, Google Scholar
• Danzon P. M. (2000) The pharmaceutical industry. , Bouckaert B., De Geest G., eds. The Encyclopedia of Law and Economics. (Edward Elgar, Cheltenham, UK) , 1055–1091.Google Scholar
• Dasgupta P. (1988) Patents, priority and imitation, or the economics of races and waiting games. Econom. J. 98(389) 66–80.Google Scholar
• DiMaggio P. J., Powell W. W. (1983) The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields. Amer. Sociol. Rev. 48(2) 147–60.Crossref, Google Scholar
• DiMasi J. A. (2001) Risks in new drug development: Approval success rates for investigational drugs. Clinical Pharmacol. Ther. 69(5) 297–307.Crossref, Google Scholar
• DiMasi J. A., Paquette C. (2004) The economics of follow-on drug research and development: Trends in entry rates and the timing of development. Pharmacoeconomics 22(2 Supplement 2) 1–14.Crossref, Google Scholar
• Dosi G. (1982) Technological paradigms and technological trajectories. Res. Policy 11(3) 147–162.Crossref, Google Scholar
• Furberg C. D., Herrington D. M., Psaty B. M. (1999) Are drugs within a class interchangeable? Lancet 354(9185) 1202–1204.Crossref, Google Scholar
• Gambardella A. (1992) Competitive advantages from in-house scientific research: The US pharmaceutical industry in the 1980s. Res. Policy 21(5) 391–407.Crossref, Google Scholar
• Garud R., Rappa M. A. (1994) A socio-cognitive model of technology evolution: The case of cochlear implants. Organ. Sci. 5(3) 344–362.Link, Google Scholar
• Garud R., Jain S., Kumaraswamy A. (2002) Institutional entrepreneurship in the sponsorship of common technological standards: The case of Sun Microsystems and Java. Acad. Management J. 45(1) 196–214.Crossref, Google Scholar
• Gittelman M., Kogut B. (2003) Does good science lead to valuable knowledge? Biotechnology firms and the evolutionary logic of citation patterns. Management Sci. 49(4) 366–382.Link, Google Scholar
• Godin B. (1996) Research and the practice of publication in industries. Res. Policy 25(4) 587–606.Crossref, Google Scholar
• Greene W. H. (2003) Econometric Analysis, 5th ed. (Prentice Hall, Upper Saddle River, NJ) .Google Scholar
• Griliches Z. (1990) Patent statistics as economic indicators: A survey. J. Econom. Literature 28(4) 1661–1707.Google Scholar
• GSAS Harvard Biotechnology Club (2000) . Retrieved September 24, 2009, http://www.thebiotechclub.org.Google Scholar
• Hansen M. T., Haas M. R. (2001) Competing for attention in knowledge markets: Electronic document dissemination in a management consulting company. Admin. Sci. Quart. 46(1) 1–28.Crossref, Google Scholar
• Hannan M., Freeman J. (1977) The population ecology of organizations. Amer. J. Sociol. 88 1116–1145.Google Scholar
• Hargadon A. B., Douglas Y. (2001) When innovations meet institutions: Edison and the design of the electric light. Admin. Sci. Quart. 46(3) 476–501.Crossref, Google Scholar
• Hausman J. A., Hall B. H., Griliches Z. (1984) Econometric models for count data with an application to the patents-R&D relationship. Econometrica 52(4) 909–938.Crossref, Google Scholar
• Henderson R., Cockburn I. (1994) Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management J. 15(S1) 63–84.Crossref, Google Scholar
• Hicks D. (1995) Published papers, tacit competencies and corporate management of the public/private character of knowledge. Indust. Corporate Change 4(2) 401–424.Crossref, Google Scholar
• Hosaka T. (1998) Use beta blockers more, studies suggest: Two new reports on heart attack patients emphasize the benefits of these drugs. Washington Post (August 25) Z07.Google Scholar
• Jones M. I., Greenfield S. M., Bradley C. P. (2001) Prescribing new drugs: Qualitative study of influences on consultants and general practitioners. British Medical J. 323(7309) 378–381.Crossref, Google Scholar
• Jones N. (2009) Ghosts still present in the medical machine. Nature 461(7262) 325.Crossref, Google Scholar
• Kalra P. A., Mamtora H., Holmes A. M., Waldek S. (1990) Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Quart. J. Medicine 77(282) 1013–1018.Crossref, Google Scholar
• Kaplan S., Tripsas M. (2008) Thinking about technology: Applying a cognitive lens to technical change. Res. Policy 37(5) 790–805.Crossref, Google Scholar
• Kennedy H. L., Rosenson R. (2002) Physicians' interpretation of “class effects”: A need for thoughtful re-evaluation. J. Amer. College Cardiol. 40(1) 19–26.Crossref, Google Scholar
• Kleschick W. A., Lubetkin S., Oliver G. R., Hutchins S. H., Peterson R. K. D. (2001) Publish or perish: A business and professional argument for private-sector scientists to publish in refereed journals. Amer. Entomologist 47(2) 69–73.Crossref, Google Scholar
• Kogut B., Zander U. (1992) Knowledge of the firm, combinative capabilities, and the replication of technology. Organ. Sci. 3(3) 383–397.Link, Google Scholar
• Landefeld C. S., Steinman M. A. (2009) The Neurontin legacy—Marketing through misinformation and manipulation. New Engl. J. Medicine 360(2) 103–106.Crossref, Google Scholar
• Lauritsen K., Havelund T., Laursen L. S., Rask-Madsen J. (1987) Withholding unfavourable results in drug company sponsored clinical trials. Lancet 1(8541) 1091.Crossref, Google Scholar
• Law M., Wald N., Morris J. (2003) Lowering blood pressure to prevent myocardial infarction and stroke: A new preventative strategy. Health Tech. Assessment 7(31) 1–94.Crossref, Google Scholar
• Lexchin J., Bero L. A., Djulbegovic B., Clark O. (2003) Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical J. 326(7400) 1167–1170.Crossref, Google Scholar
• Liebeskind J. (1996) Knowledge, strategy, and the theory of the firm. Strategic Management J. 17(Winter special issue) 93–107.Crossref, Google Scholar
• Macher J. T., Boerner C. S. (2006) Experience and scale and scope economies: Trade-offs and performance in development. Strategic Management J. 27(9) 845–865.Crossref, Google Scholar
• Mansfield E., Schwartz M., Wagner S. (1981) Imitation costs and patents: An empirical study. Econom. J. 91(364) 907–918.Google Scholar
• Mayor S. (2006) NICE removes β blockers as first line treatment for hypertension. British Medical J. 333(7557) 8.Crossref, Google Scholar
• Merton R. K. (1973) The Sociology of Science: Theoretical and Empirical Investigations. (Chicago University Press, Chicago) .Google Scholar
• Meyer J. W., Rowan B. (1977) Institutionalized organizations: Formal structure as myth and ceremony. Amer. J. Sociol. 83(2) 340–363.Crossref, Google Scholar
• Mitchell W. (1989) Whether and when? Probability and timing of incumbents' entry into emerging industrial subfields. Admin. Sci. Quart. 34(2) 208–230.Crossref, Google Scholar
• Nagourney E. (2005) Front line against hypertension is under siege. New York Times (November 1) F6.Google Scholar
• Nelson R. R. (1959) The simple economics of basic scientific research. J. Political Econom. 67(3) 297–306.Crossref, Google Scholar
• Nelson R. R. (1982) Government and Technical Progress: A Cross-Industry Analysis. (Pergamon, New York) .Google Scholar
• Nelson R. R. (1991) Why do firms differ, and how does it matter? Strategic Management J. 12(S2) 61–74.Crossref, Google Scholar
• Nelson R. R., Winter S. G. (1982) An Evolutionary Theory of Economic Change. (Belknap Press of Harvard University Press, Cambridge, MA) .Google Scholar
• Noll R. G. (1989) Economic perspectives on the politics of regulation. , Schmalensee R., Willig R., eds. Handbook of Industrial Organization, Vol. 2. (Elsevier, Amsterdam) , 1253–1287.Google Scholar
• Olson M. K. (1999) Agency rulemaking, political influences, regulation, and industry compliance. J. Law Econom. 15(3) 573–601.Crossref, Google Scholar
• Olson M. K. (2004) Are novel drugs more risky for patients than less novel drugs? J. Health Econom. 23(6) 1135–1158.Crossref, Google Scholar
• Penner-Hahn P., Shaver J. M. (2005) Does international research and development increase patent output? An analysis of Japanese pharmaceutical firms. Strategic Management J. 26(2) 121–140.Crossref, Google Scholar
• Peteraf M. A. (1993) The cornerstones of competitive advantage: A resource-based view. Strategic Management J. 14(3) 179–191.Crossref, Google Scholar
• Pisano G. P. (2006) Science Business: The Promise, the Reality and the Future of Biotech. (Harvard Business School Press, Boston) .Google Scholar
• Rao H. (1994) The social construction of reputation: Certification contests, legitimation, and the survival of organizations in the American automobile industry: 1895–1912. Strategic Management J. 15(S1) 29–44.Crossref, Google Scholar
• Ray W. A., Downey W., Griffin M. R., Melton L. J. (1989) Long-term use of thiazide diuretics and risk of hip fracture. Lancet 333(8640) 687–690.Crossref, Google Scholar
• Reuben B. G., Wittcoff H. A. (1989) Pharmaceutical Chemicals in Perspective. (John Wiley & Sons, New York) .Google Scholar
• Rosenberg N.. (1982) How exogenous is science? , Rosenberg N., ed. Inside the Black Box: Technology and Economics. (Cambridge University Press, Cambridge, UK) , 141–162.Google Scholar
• Rosenberg N. (1990) Why do firms do basic research (with their own money)? Res. Policy 19(2) 165–174.Crossref, Google Scholar
• Scriabine A. (1999) Discovery and development of major drugs currently in use. , Landau R., Achilladelis B., Scriabine A., eds. Pharmaceutical Innovation: Revolutionizing Human Health. (Chemical Heritage Press, Philadelphia) , 148–270.Google Scholar
• Sharma A., Lacey N. (2004) Linking product development outcomes to market valuation of the firm: The case of U.S. pharmaceutical industry. J. Product Innovation Management 21(5) 297–308.Crossref, Google Scholar
• Skinner D. J. (1994) Why firms voluntarily disclose bad news. J. Accounting Res. 32(1) 38–60.Crossref, Google Scholar
• Strang D., Meyer J. W. (1993) Institutional conditions for diffusion. Theory Soc. 22(4) 487–511.Crossref, Google Scholar
• Thomke S., Kuemmerle W. (2002) Asset accumulation, interdependence and technological change: Evidence from pharmaceutical drug discovery. Strategic Management J. 23(7) 619–635.Crossref, Google Scholar
• Thompson J. D. (1967) Organizations in Action. (McGraw-Hill, New York) .Google Scholar
• Trajtenberg M. (1990) A penny for your quotes: Patent citations and the value of innovations. RAND J. Econom. 21(1) 172–187.Crossref, Google Scholar
• Travis J. (2005) Saving the mind faces high hurdles. Science 309(5735) 731–734.Crossref, Google Scholar
• Tripsas M. (1997) Unraveling the process of creative destruction: Complementary assets and firm survival in the typesetter industry. Strategic Management J. 18(S1) 119–142.Crossref, Google Scholar
• Tushman M. L., Anderson P. (1986) Technological discontinuities and organizational environments. Admin. Sci. Quart. 31(3) 439–465.Crossref, Google Scholar
• Vaczek D. (2005) Top 200 prescription drugs of 2004. Pharmacy Times (May 1). . http://www.pharmacytimes.com/publications/issue/2005/2005-05/2005-05-9582.Google Scholar
• van den Belt H., Rip A. (1987) The Nelson-Winter-Dosi model and synthetic dye chemistry. , Bijker W. E., Hughes T. P., Pinch T. J., eds. The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology. (MIT Press, Cambridge, MA) , 135–158.Google Scholar
• Vogel G. (1997) Publishing sensitive data: Who calls the shots? Long-suppressed study finally sees light of day. Science 276(5312) 525–526.Crossref, Google Scholar
• Wooldridge J. M. (2002) Econometric Analysis of Cross Section and Panel Data. (MIT Press, Cambridge, MA) .Google Scholar
• Ziman J. M. (1968) Public Knowledge: An Essay Concerning the Social Dimension of Science. (Cambridge University Press, Cambridge, UK) .Google Scholar